CN103648282B - 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途 - Google Patents

噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途 Download PDF

Info

Publication number
CN103648282B
CN103648282B CN201280035142.0A CN201280035142A CN103648282B CN 103648282 B CN103648282 B CN 103648282B CN 201280035142 A CN201280035142 A CN 201280035142A CN 103648282 B CN103648282 B CN 103648282B
Authority
CN
China
Prior art keywords
purposes according
thiazides
cells
class compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280035142.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103648282A (zh
Inventor
让-弗朗索瓦·罗西尼奥尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Priority to CN201611145115.5A priority Critical patent/CN107096032A/zh
Publication of CN103648282A publication Critical patent/CN103648282A/zh
Application granted granted Critical
Publication of CN103648282B publication Critical patent/CN103648282B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F11/00—Rotary presses or machines having forme cylinders carrying a plurality of printing surfaces, or for performing letterpress, lithographic, or intaglio processes selectively or in combination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/18—Impression cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/193—Transfer cylinders; Offset cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/025—Multicolour printing or perfecting on sheets or on one or more webs, in one printing unit
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/04—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs
    • B41F7/06—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs for printing on sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/08—Rotary lithographic machines for offset printing using one transfer cylinder co-operating with several forme cylinders for printing on sheets or webs, e.g. sampling of colours on one transfer cylinder
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F9/00—Rotary intaglio printing presses
    • B41F9/02—Rotary intaglio printing presses for multicolour printing
    • B41F9/021—Sheet printing presses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280035142.0A 2011-05-16 2012-05-15 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途 Expired - Fee Related CN103648282B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611145115.5A CN107096032A (zh) 2011-05-16 2012-05-15 在有需要的对象中刺激免疫应答的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486728P 2011-05-16 2011-05-16
US61/486,728 2011-05-16
PCT/US2012/037958 WO2012158699A1 (en) 2011-05-16 2012-05-15 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611145115.5A Division CN107096032A (zh) 2011-05-16 2012-05-15 在有需要的对象中刺激免疫应答的方法

Publications (2)

Publication Number Publication Date
CN103648282A CN103648282A (zh) 2014-03-19
CN103648282B true CN103648282B (zh) 2017-02-15

Family

ID=47175068

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280035142.0A Expired - Fee Related CN103648282B (zh) 2011-05-16 2012-05-15 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
CN201611145115.5A Pending CN107096032A (zh) 2011-05-16 2012-05-15 在有需要的对象中刺激免疫应答的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611145115.5A Pending CN107096032A (zh) 2011-05-16 2012-05-15 在有需要的对象中刺激免疫应答的方法

Country Status (15)

Country Link
US (3) US20120294831A1 (https=)
EP (1) EP2709453B1 (https=)
JP (3) JP6138764B2 (https=)
KR (1) KR102037162B1 (https=)
CN (2) CN103648282B (https=)
AU (1) AU2012255962B2 (https=)
BR (1) BR112013029505A2 (https=)
CA (1) CA2836253C (https=)
DK (1) DK2709453T3 (https=)
EA (1) EA024063B1 (https=)
ES (1) ES2767304T3 (https=)
IL (1) IL229459B (https=)
MX (2) MX2013013115A (https=)
WO (1) WO2012158699A1 (https=)
ZA (1) ZA201308617B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648282B (zh) * 2011-05-16 2017-02-15 罗马克实验室有限公司 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
WO2014145631A1 (en) * 2013-03-15 2014-09-18 The Broad Institute, Inc. Dendritic cell response gene expression, compositions of matters and methods of use thereof
KR101508611B1 (ko) 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 아파티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
KR101508610B1 (ko) * 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 다코미티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
WO2015030504A1 (ko) * 2013-09-02 2015-03-05 가톨릭대학교 산학협력단 비소세포폐암 치료제를 유효성분으로 포함하는 톡소포자충감염증의 예방 또는 치료용 약학 조성물
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
CN108289961A (zh) 2016-03-31 2018-07-17 罗马克实验室有限公司 用于治疗病毒性感染的噻唑化物化合物
EA202191466A1 (ru) 2016-04-11 2021-12-31 Женфит Способы лечения холестатических и фибротических заболеваний
CN105998036B (zh) * 2016-05-19 2018-07-27 洛阳市兽药厂 一种猪禽用复方磺胺硝唑尼特可溶性粉
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN118903087A (zh) 2019-07-26 2024-11-08 埃斯佩尔维塔治疗股份有限公司 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
CN113398125B (zh) 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease
US11730712B2 (en) 2021-01-25 2023-08-22 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
WO2023077711A1 (zh) * 2021-11-03 2023-05-11 南方科技大学 预防前列腺癌的药剂的筛选方法及硝唑尼特在制药中的应用
CN114231611A (zh) * 2021-12-07 2022-03-25 中南大学湘雅二医院 干扰素诱导基因ifit3对b淋巴细胞活化及分化影响的研究方法
CN116539887A (zh) * 2023-01-09 2023-08-04 重庆医科大学 Psme1作为药物靶点在筛选或制备治疗乙型肝炎的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958038A (en) * 1997-11-07 1999-09-28 S3 Incorporated Computer processor with two addressable memories and two stream registers and method of data streaming of ALU operation
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US20100260797A1 (en) * 2007-12-06 2010-10-14 Emmanuel Jules Hanon Influenza composition
US20100330173A1 (en) * 2009-06-26 2010-12-30 Romark Laboratories L.C. Compounds and methods for treating influenza
US20110098248A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
CA2604640A1 (en) 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
US20110223131A1 (en) * 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9439878B2 (en) * 2010-06-03 2016-09-13 Douglas Tyler McKenzie Use of lumefantrine and related compounds in the treatment of cancer
EP2725902A4 (en) * 2011-04-06 2015-06-24 Univ Princeton ANTIVIRAL COMBINATION THERAPY
CN103648282B (zh) * 2011-05-16 2017-02-15 罗马克实验室有限公司 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5958038A (en) * 1997-11-07 1999-09-28 S3 Incorporated Computer processor with two addressable memories and two stream registers and method of data streaming of ALU operation
US20100260797A1 (en) * 2007-12-06 2010-10-14 Emmanuel Jules Hanon Influenza composition
US20100330173A1 (en) * 2009-06-26 2010-12-30 Romark Laboratories L.C. Compounds and methods for treating influenza
US20110098248A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors

Also Published As

Publication number Publication date
EP2709453A4 (en) 2014-11-19
JP2017149764A (ja) 2017-08-31
KR20140028034A (ko) 2014-03-07
KR102037162B1 (ko) 2019-10-29
CN107096032A (zh) 2017-08-29
IL229459A0 (en) 2014-01-30
CA2836253C (en) 2021-02-16
ES2767304T3 (es) 2020-06-17
BR112013029505A2 (pt) 2020-01-07
AU2012255962B2 (en) 2016-05-12
US20120294831A1 (en) 2012-11-22
EP2709453B1 (en) 2019-10-23
DK2709453T3 (da) 2020-01-20
US20190291404A1 (en) 2019-09-26
JP2014513725A (ja) 2014-06-05
MX2013013115A (es) 2014-02-27
US10814612B2 (en) 2020-10-27
IL229459B (en) 2021-05-31
JP6138764B2 (ja) 2017-05-31
EA024063B1 (ru) 2016-08-31
US10336058B2 (en) 2019-07-02
CA2836253A1 (en) 2012-11-22
MX378726B (es) 2025-03-11
US20180126722A1 (en) 2018-05-10
EP2709453A1 (en) 2014-03-26
EA201391616A1 (ru) 2014-05-30
WO2012158699A1 (en) 2012-11-22
CN103648282A (zh) 2014-03-19
ZA201308617B (en) 2020-07-29
JP2019052175A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
CN103648282B (zh) 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
AU2012255962A1 (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
JP2023011840A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
JP2013522302A (ja) 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
EP2445506A1 (en) The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
TW201035099A (en) Therapeutic composition
JP2010520284A (ja) Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト
Arico et al. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
Khatri et al. Nitazoxanide/Camostat combination for COVID-19: an unexplored potential therapy
KR20100126390A (ko) 톨-유사 수용체 3의 선택적인 작용제
Bergman et al. Interferons as therapeutic agents for infectious diseases
AU2018211247B2 (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
HK1240084A1 (en) A method of stimulating an immune response in a subject in need thereof
HK1192415B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
HK1192415A (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
JP2009504706A (ja) ＨＢＶ処置のためのＰＥＧ−ＩＦＮαおよびリバビリン
CN1723025A (zh) 用于对抗hiv的3tc/azt抗性株的二氧戊环基胸腺嘧啶及其组合物
Blanco et al. Toxoplasma gondii and Its Relation
HK1136158A (en) Restrictive agonist of toll-like receptor 3 (tlr3)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192415

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192415

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170215

Termination date: 20210515